What is the primary indication for Tekturna (aliskiren)?

The primary indication for Tekturna (aliskiren) is the treatment of hypertension, which is high blood pressure. Aliskiren is a direct renin inhibitor that works by inhibiting the activity of renin, an enzyme involved in the renin-angiotensin-aldosterone system (RAAS). By lowering the levels of angiotensin I and II, the medication reduces blood vessel constriction and ultimately leads to a decrease in blood pressure.

In managing hypertension, aliskiren can help reduce the risk of cardiovascular events and improve overall heart health. It is important to note that while other medications may be indicated for heart failure, diabetes management, or cholesterol reduction, Tekturna's specific role is focused on lowering blood pressure, making its primary indication definitive in treating hypertension.